Ketryx, the agentic continuous compliance platform for safety-critical product development, announced that William A. Hawkins, former Chairman and CEO of Medtronic, has joined its Board of Directors. Hawkins also participated in the company’s Series B financing, signaling strong investor confidence in Ketryx’s mission to streamline regulatory compliance for medical devices, pharmaceuticals, and robotics.
Hawkins brings decades of leadership experience from Medtronic, where he served as CEO from 2007 to 2011 and Chairman until 2014. Under his guidance, Medtronic grew into the world’s largest standalone medical technology company. His expertise in scaling complex, regulated businesses will be instrumental as Ketryx expands its platform to help life sciences teams accelerate product development while maintaining compliance.
Ketryx’s platform addresses a critical bottleneck in the industry: the integration of AI into safety-critical workflows. By automatically generating compliant documentation, maintaining continuous traceability, and enabling safe and verifiable AI at scale, Ketryx reduces manual work by up to 90 percent. The platform overlays existing tools, allowing teams to close compliance gaps without disrupting established processes.
“Bill’s track record of leading innovation in highly regulated environments makes him an invaluable addition to our board,” said Ketryx CEO. “His insights will help us scale our platform to meet the growing demand for AI-driven compliance solutions.”
Hawkins commented, “Ketryx is uniquely positioned to solve one of the biggest challenges in life sciences: how to harness AI without compromising safety or regulatory compliance. I look forward to contributing to their mission.”
Trusted by four of the world’s top five medical device manufacturers, Ketryx is transforming product lifecycles to deliver safer products faster. For more information, visit www.ketryx.com.
